Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule
- PMID: 3162327
Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule
Abstract
The pharmacokinetics and tissue penetration of five quinolones into inflammatory exudate were studied in healthy volunteers. The compounds studied were norfloxacin (400 mg orally), enoxacin (400 mg intravenously and 600 mg orally), ciprofloxacin (100 mg intravenously and 500 mg orally), ofloxacin (600 mg orally), and pefloxacin (400 mg intravenous). Orally administered ofloxacin and ciprofloxacin were the most rapidly absorbed (time to maximal serum level, 1.2 hours) and enoxacin the least (1.9 hours). The serum levels attained were highest in the case of ofloxacin (after an allowance was made for the higher dose administered). The serum elimination half-lives were as follows: norfloxacin, 3.75 hours; ciprofloxacin, 3.9 hours (oral) and 4.0 hours (intravenous); ofloxacin, 7.0 hours; enoxacin, 6.2 hours (oral) and 5.1 hours (intravenous); and pefloxacin, 10.5 hours. All agents penetrated well into a mild inflammatory exudate. The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide). A dosing schedule for the quinolones was proposed on the basis of pharmacokinetic parameters and microbiologic activity.
Similar articles
-
The comparative pharmacokinetics of five quinolones.J Antimicrob Chemother. 1986 Nov;18 Suppl D:71-81. doi: 10.1093/jac/18.supplement_d.71. J Antimicrob Chemother. 1986. PMID: 3468102
-
Steady-state kinetics of the quinolone derivatives ofloxacin, enoxacin, ciprofloxacin and pefloxacin during maintenance treatment with theophylline.Drugs. 1987;34 Suppl 1:159-69. doi: 10.2165/00003495-198700341-00034. Drugs. 1987. PMID: 3481317
-
Comparative pharmacokinetics of new quinolones.Drugs. 1987;34 Suppl 1:21-5. doi: 10.2165/00003495-198700341-00006. Drugs. 1987. PMID: 3481323
-
Pharmacokinetics of ciprofloxacin.Infection. 1988;16 Suppl 1:S3-13. doi: 10.1007/BF01650500. Infection. 1988. PMID: 3286512 Review.
-
Clinical pharmacokinetics of the newer antibacterial 4-quinolones.Clin Pharmacokinet. 1988 Feb;14(2):96-121. doi: 10.2165/00003088-198814020-00003. Clin Pharmacokinet. 1988. PMID: 3282749 Review.
Cited by
-
Sequential antibiotic therapy: Effective cost management and patient care.Can J Infect Dis. 1995 Nov;6(6):306-15. doi: 10.1155/1995/165848. Can J Infect Dis. 1995. PMID: 22550411 Free PMC article.
-
Use of fluoroquinolone antimicrobial agents by cardiovascular and cardiopulmonary surgeons.Tex Heart Inst J. 1990;17(1):12-21. Tex Heart Inst J. 1990. PMID: 15227184 Free PMC article. No abstract available.
-
Intracellular activities of roxithromycin used alone and in association with other drugs against Mycobacterium avium complex in human macrophages.Antimicrob Agents Chemother. 1995 Apr;39(4):976-8. doi: 10.1128/AAC.39.4.976. Antimicrob Agents Chemother. 1995. PMID: 7786006 Free PMC article.
-
Bioavailability and pharmacokinetics of ofloxacin in healthy volunteers.Antimicrob Agents Chemother. 1991 Feb;35(2):384-6. doi: 10.1128/AAC.35.2.384. Antimicrob Agents Chemother. 1991. PMID: 2024973 Free PMC article. Clinical Trial.
-
In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin.Antimicrob Agents Chemother. 1991 Sep;35(9):1933-6. doi: 10.1128/AAC.35.9.1933. Antimicrob Agents Chemother. 1991. PMID: 1952872 Free PMC article.